Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Synthetic Hydrogel (aka Squishy Gel) Could Revolutionize Arthritis Treatment

Richard Quinn  |  April 8, 2014

Although clinical applications are still years away, rheumatologists should start getting excited about research to develop a synthetic hydrogel—squishy gel, for short—that could be injected into arthritic joints to time release antiinflammatory medication.

A lead author of a new report on the production of the so-called mechano-responsive gels says that while it’s likely years away from use by patients, her research is an exciting development for patients whose osteoarthritis flares up when joints compress.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“On the one hand, it can combat the inflammatory response,” says Xinqiao Jia, PhD, associate professor of materials science and engineering at the University of Delaware in Newark. “Down the road, if you can release a therapeutic drug … that would be the ultimate goal.”

The study was published in the American Chemical Society’s Biomacromolecules.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Few existing hydrogels respond to the pressure produced by joint compression, meaning development of such squishy gels could be a revolutionary treatment. The research team is currently conducting animal testing, which Dr. Jia says could take another two years.

Preliminary results are encouraging and, if all goes well, human trials could begin in a few years. The theory is to eventually create a gel that would include a chemical compound capable of helping repair, restore or regenerate cartilage in a joint.
“Incorporating mechano-responsive modules in synthetic matrices offers a novel strategy to harvest mechanical stress present in the healing wounds to initiate tissue repair,” the study says. But Dr. Jia cautions that this kind of research is cutting edge and could take years to become patient ready, as well as requiring extensive grants to fund the work.

“I’m excited … but I don’t want to give people false hope that they can immediately expect this,” she adds. “We have a lot of work to do.”

(posted April 8, 2014)


Richard Quinn is a freelance writer in New Jersey.

Reference

  1. Xiao L, Tong Z, Chen Y, et al. Hyaluronic acid-based hydrogels containing covalently integrated drug depots: Implication for controlling inflammation in mechanically stressed tissues. Biomacromolecules. 2013;14:3808–3819.

Share: 

Filed under:Research Rheum Tagged with:JIA

Related Articles
    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    A Possible Diagnostic Tool: RheumMadness 2022 AI: JIA Subtypes Scouting Report

    February 14, 2022

    Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.

    FDA Approves Meloxicam Injection & OTC Diclofenac Sodium Topical Gel for Pain Management

    April 13, 2020

    The FDA has approved two pain medications: meloxicam in an injection and over-the-counter diclofenac sodium topical gel 1%…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences